## Neil D Gross

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6906147/publications.pdf

Version: 2024-02-01

24 papers 1,249 citations

840585 11 h-index 552653
26
g-index

26 all docs

26 docs citations

26 times ranked 2290 citing authors

#	Article	IF	CITATIONS
1	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	15.2	592
2	Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). Journal of Clinical Oncology, 2022, 40, 138-149.	0.8	162
3	Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration. British Journal of Cancer, 2020, 123, 1456-1463.	2.9	65
4	Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clinical Cancer Research, 2020, 26, 3211-3219.	3.2	64
5	Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2021, 27, 4557-4565.	3.2	61
6	The impact of <scp>COVID</scp> â€19 on head and neck cancer diagnosis and disease extent. Head and Neck, 2021, 43, 1890-1897.	0.9	50
7	Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach. Oral Oncology, 2019, 94, 47-57.	0.8	32
8	A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. Oral Oncology, 2020, 110, 104797.	0.8	32
9	Lessons learned from the INHANCE consortium: An overview of recent results on head and neck cancer. Oral Diseases, 2021, 27, 73-93.	1.5	31
10	Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head and Neck, 2018, 40, 79-85.	0.9	25
11	<scp>Highly conformal</scp> reirradiation in patients with prior oropharyngeal radiation: Clinical efficacy and toxicity outcomes. Head and Neck, 2020, 42, 3326-3335.	0.9	14
12	Transoral robotic surgery adoption and safety in treatment of oropharyngeal cancers. Cancer, 2022, 128, 685-696.	2.0	13
13	Age at start of using tobacco on the risk of head and neck cancer: Pooled analysis in the International Head and Neck Cancer Epidemiology Consortium (INHANCE). Cancer Epidemiology, 2019, 63, 101615.	0.8	12
14	Outcomes after salvage for HPV-positive recurrent oropharyngeal cancer treated with primary radiation. Oral Oncology, 2021, 113, 105125.	0.8	12
15	Association between postoperative complications and longâ€term oncologic outcomes following total laryngectomy: 10â€year experience at MD Anderson Cancer Center. Cancer, 2020, 126, 4905-4916.	2.0	10
16	PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells. Journal of Cellular and Molecular Medicine, 2020, 24, 2444-2450.	1.6	10
17	Homologous recombination enhances radioresistance in hypopharyngeal cancer cell line by targeting DNA damage response. Oral Oncology, 2020, 100, 104469.	0.8	9
18	Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE consortium. Oral Diseases, 2023, 29, 1565-1578.	1.5	9

#	Article	IF	CITATION
19	Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer, 2021, 127, 4413-4420.	2.0	7
20	Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer, 2021, 127, 1238-1245.	2.0	6
21	Dysphagia profiles after primary transoral robotic surgery or radiation for oropharyngeal cancer: A registry analysis. Head and Neck, 2021, 43, 2883-2895.	0.9	6
22	A genetic variant within <i>MDM4</i> 3′UTR miRNA binding site is associated with HPV16â€positive tumors and survival of oropharyngeal cancer. Molecular Carcinogenesis, 2019, 58, 2276-2285.	1.3	5
23	Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. European Journal of Cancer, 2021, 144, 169-177.	1.3	3
24	Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head and Neck, 2021, 43, 1592-1603.	0.9	2